Envision Healthcare (EVHC) Earns Neutral Rating from Analysts at Piper Jaffray Companies
Piper Jaffray Companies assumed coverage on shares of Envision Healthcare (NYSE:EVHC) in a research report sent to investors on Wednesday morning, Marketbeat Ratings reports. The firm issued a neutral rating and a $35.00 price target on the stock.
Several other research firms have also recently commented on EVHC. BidaskClub cut Envision Healthcare from a sell rating to a strong sell rating in a research note on Thursday, August 17th. Jefferies Group set a $71.00 target price on Envision Healthcare and gave the company a buy rating in a research note on Thursday, August 24th. Bank of America reduced their target price on Envision Healthcare from $72.00 to $60.00 and set a buy rating for the company in a research note on Monday, October 9th. Canaccord Genuity reiterated a buy rating and set a $32.00 target price (down from $68.00) on shares of Envision Healthcare in a research note on Thursday, November 2nd. Finally, Citigroup cut Envision Healthcare from a buy rating to a neutral rating and set a $31.00 target price for the company. in a research note on Thursday, November 2nd. One equities research analyst has rated the stock with a sell rating, seven have issued a hold rating, nine have given a buy rating and one has assigned a strong buy rating to the stock. The company presently has an average rating of Buy and an average price target of $46.06.
Envision Healthcare (EVHC) opened at $34.30 on Wednesday. The company has a market capitalization of $4,146.49, a P/E ratio of 10.59, a PEG ratio of 0.89 and a beta of 0.57. The company has a debt-to-equity ratio of 0.89, a quick ratio of 3.00 and a current ratio of 3.01. Envision Healthcare has a one year low of $23.77 and a one year high of $73.00.
Envision Healthcare declared that its Board of Directors has initiated a stock buyback program on Monday, September 18th that permits the company to buyback $250.00 million in outstanding shares. This buyback authorization permits the company to purchase up to 4.5% of its stock through open market purchases. Stock buyback programs are typically a sign that the company’s board of directors believes its stock is undervalued.
A number of institutional investors and hedge funds have recently made changes to their positions in EVHC. Commonwealth Bank of Australia increased its position in Envision Healthcare by 24.3% in the second quarter. Commonwealth Bank of Australia now owns 2,096 shares of the company’s stock worth $130,000 after buying an additional 410 shares during the period. LMR Partners LLP acquired a new stake in Envision Healthcare in the second quarter worth $205,000. Palisade Capital Management LLC NJ acquired a new stake in Envision Healthcare in the third quarter worth $229,000. Cutter & CO Brokerage Inc. increased its position in Envision Healthcare by 11.1% in the second quarter. Cutter & CO Brokerage Inc. now owns 3,668 shares of the company’s stock worth $230,000 after buying an additional 367 shares during the period. Finally, Flinton Capital Management LLC increased its position in Envision Healthcare by 18.7% in the second quarter. Flinton Capital Management LLC now owns 4,464 shares of the company’s stock worth $280,000 after buying an additional 704 shares during the period.
About Envision Healthcare
Envision Healthcare Holdings, Inc, formerly CDRT Holding Corporation, is a holding company. The Company, through its subsidiary, provides physician-led medical services in the United States. It operates in two segments: EmCare Holdings, Inc (EmCare) and American Medical Response, Inc (AMR). Its EmCare segment is a provider of integrated facility-based and post-acute care physician services to healthcare facilities in the United States.
Receive News & Ratings for Envision Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Envision Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.